Ignite Creation Date:
2024-05-06 @ 8:18 AM
Last Modification Date:
2024-10-26 @ 11:58 AM
Study NCT ID:
NCT02710149
Status:
UNKNOWN
Last Update Posted:
2019-06-25
First Post:
2015-11-08
Brief Title:
A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies
Sponsor:
Southwest Hospital China
Organization:
Southwest Hospital China
Study Overview
Official Title:
A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies
Status:
UNKNOWN
Status Verified Date:
2019-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to explore the therapeutic effect of CD20-targeted chimeric antigen receptor TCAR-T cells in the treatment of B cell malignancies
Detailed Description:
The anti-CD20 antibody has been broadly used in the treatment of B cell malignancies and exhibited good clinical outcomes The CD19-targeted CAR-T has shown exellent therapeutic efficiency in B cell malignanciesespecially in acute lymphocytic leukemia However patients treated with CD19-targeted CAR-T may face relapse of CD19 mutation Other targets aimed CAR-T is in need Therefore we constructed CD20-targeted CAR-T cells and hope to start a clinicaltrial to explore the therapeutic effect of CD20-targeted CAR-T cells in the treatment of B cell malignancies
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None